Fertility preservation is an important issue for young women diagnosed with breast cancer. The most well-established options for fertility preservation in cancer patients, embryo and oocyte cryopreservation, have not been traditionally offered to breast cancer patients as estradiol rise during standard stimulation protocols may not be safe for those patients. Potentially safer stimulation protocols using tamoxifen and aromatase inhibitors induce lower levels of estradiol whereas similar results in terms of number of oocyte and embryo obtained to standard protocols. Cryopreservation of immature oocytes and ovarian cortical tissue, both still experimental methods, are also fertility preservation options for breast cancer patients.
*Karolinska Institute, Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Obstetrics and Gynecology
†Fertility Unit, Karolinska University Hospital Huddinge, Stockholm, Sweden
‡Institute for Fertility Preservation, Department of Obstetrics and Gynecology, NY Medical College-Westchester Medical Center, Valhalla, New York
Dr Rodriguez-Wallberg is supported by research grants from The Swedish Society of Medical Research and The Swedish Society of Medicine. Professor Kutluk Oktay is supported by NIH grant HD053112A.
Correspondence: Kutluk Oktay, MD, FACOG, Institute for Fertility Preservation, Department of Obstetrics and Gynecology, NY Medical College, Valhalla, NY. E-mail: firstname.lastname@example.org